Microbiome Diagnostics Market by Product (Kits & Reagents, Instruments), Technology (16s rRNA Sequencing, Shot Gun Metagenomics, Metatranscriptomics), Sample (Fecal, Saliva, Skin), Application (GI, Metabolic Disorders) - Global Forecast to 2028
Market Growth Outlook Summary
The global microbiome diagnostics market growth forecasted to transform from $146 million in 2023 to $300 million by 2028, driven by a CAGR of 15.5%. Market growth is driven by the rising incidence of chronic diseases, collaborative efforts between microbiome industry and academic institutes, and growing demand of personalized medicine.
Attractive Opportunities in the Microbiome Diagnostics Market
To know about the assumptions considered for the study, Request for Free Sample Report
Microbiome Diagnostics Market Dynamics
DRIVER: Collaborative efforts between the microbiome industry and academia for microbiome research
The human microbiome is a rapidly growing field of research, and there has been a significant surge in industry-academia collaborations centered around microbiome research. These collaborations unite academic researchers and industry partners to develop novel microbiome-based diagnostic products, as well as to enhance our understanding of the microbiome’s role in health and disease.
Overall, the increasing number of industry-academia collaborations focused on microbiome research propels the development of the field. These provide opportunities for the development of new microbiome-based diagnostic products and facilitate the translation of basic research findings into clinical applications. These collaborations also help bridge the gap between academia and the microbiome industry, bringing together different areas of expertise and resources to enhance our understanding of the human microbiome.
RESTRAINTS: End-user budget constraints in developing countries
In developing countries, academic R&D is mostly dependent on external funding. NGS technology is mostly used for microbiome analysis. Despite continuous efforts by governments and private bodies to provide funds for research across the globe, various research and academic institutes face budget constraints regarding the purchase and use of advanced and premium-priced equipment and technologies. Although the price of NGS sequencing has declined, NGS sequencers continue to be costly.
OPPORTUNITY: Increased collaboration of key players and small innovative companies to work on new microbiome technologies
With several small innovative players operating in the market, there are various high-growth opportunities for key stakeholders to buy out companies to study microbiomes in the hope of identifying various microbiome diagnostic kits, biomarkers targets for various indications, such as obesity, liver disorders, diabetes, and metabolic disorders. Many market leaders focus on strategic collaborations and partnerships to increase their product pipelines with well-organized research and development techniques. In the last two years, there have been several collaborations and partnerships involving major companies.
CHALLENGE: Adverse impact of complex regulatory policies on commercialization of microbiome
The commercialization of microbiomes is a complex process impacted by a range of regulatory policies and guidelines. These policies are implemented to ensure the safety and efficacy of microbiome-based products and services, but they can also create significant barriers to commercialization and growth in the microbiome-based diagnostics market.
Microbiome Diagnostics Market Ecosystem/Market Map
In 2022, kits and reagents accounted for the largest share in the microbiome diagnostics industry, by product.
The microbiome diagnostics market is segmented into kits & reagents, and instruments. Kits & reagents accounted for the largest share of the microbiome-based diagnostics market in 2022 by product. The repeat purchases and consumption of kits and reagents for diagnostic procedures as compared to the instruments, which have a longer shelf time and can be used for multiple procedures, is expected to contribute to the significant share of the technology segment.
In 2022, fecal segment accounted for the largest share in the microbiome diagnostics industry, by sample.
Based on sample, the microbiome diagnostics market is segmented into fecal, saliva, skin and other samples. In 2022, fecal accounted for the largest share of the microbiome diagnostics market, by sample. The increasing incidences of diseases, and increasing demand for personalized medicine will drive the market growth.
In 2022, hospitals accounted for the largest share in the microbiome diagnostics industry, by end user.
The microbiome diagnostics market is segmented into academic and research institutes, hospitals, pharmaceutical and biotechnology companies and other end users. Hospitals accounted for the largest share of the microbiome-based diagnostics market by end user. The share of the end-user segment is owing to the rising incidence of diseases such as metabolic disorders, gastrointestinal diseases etc.
In 2022, North America accounted for the largest share of the microbiome diagnostics industry.
The global microbiome diagnostics market is segmented into five major regions: North America, Europe, the Asia Pacific, Rest of the World. North America accounted for the largest share of the microbiome-based diagnostics market in 2022. The increasing incidences of diseases, the collaboration between microbiome research and academic institutes for microbiome research, growing demand for personalized medicine in the region contribute to this regional segment’s large share.
To know about the assumptions considered for the study, download the pdf brochure
The major players in microbiome diagnostics market are DNA Genotek (Canada), Genetic Analysis AS (Norway), and Microba Life Sciences (US). These players’ market leadership is due to their broad product portfolios and vast global footprint. These dominant market players have advantages, including strong research and development budgets, better marketing and distribution networks, and established brand recognition.
Scope of the Microbiome Diagnostics Industry
Report Metric |
Details |
Market Revenue in 2023 |
$146 million |
Projected Revenue by 2028 |
$300 million |
Revenue Rate |
Poised to Grow at a CAGR of 15.5% |
Market Driver |
Collaborative efforts between the microbiome industry and academia for microbiome research |
Market Opportunity |
Increased collaboration of key players and small innovative companies to work on new microbiome technologies |
This report categorizes the microbiome diagnostics market to forecast revenue and analyze trends in each of the following submarkets:
By Product
- Reagents & Kits
- Instruments
By Technology
- 16S rRNA Sequencing
- Shot Gun Metagenomics
- Metatranscriptomics
- Other Technology
By Sample
- Feces
- Saliva
- Skin
- Other Sample
By Application
-
Disease Diagnostics Application
- Gastrointestinal Disorders
- Metabolic Diseases
- Other Application
- Research Application
By End User
- Hospitals
- Academic and Research Institutes
- Biotechnology and Pharmaceutical Companies
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Rest of Europe
-
Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Rest of the World
Recent Developments of Microbiome Diagnostics Industry:
- In 2023, The Genetic Analysis (Norway) entered into an agreement with Eagle Biosciences Inc. (US) through its distributors with an undisclosed partner. A high-volume lab company providing laboratory diagnostics to clinics, public health departments and research universities in the US.
- In 2022, DNA Genotek (Canada) Launched OMNIgene GUT OMR-205. This product allows for the stabilization, self-collection, storage and transportation of both microbial DNA and RNA at ambient temperature for gut microbiome profiling.
- In 2022, Genetic Analysis (Norway) company entered into an agreement with Microbiome Research Pvt. Ltd. to launch GA-map technology in India.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global microbiome diagnostics Market?
The global microbiome diagnostics market boasts a total revenue value of $300 million by 2028.
What is the estimated growth rate (CAGR) of the global microbiome diagnostics Market?
The global microbiome diagnostics market has an estimated compound annual growth rate (CAGR) of 15.5% and a revenue size in the region of $146 million in 2023. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
The objective of the study is to analyze the key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies. To track companies’ developments such as product launches and approvals, expansions, and partnerships of the leading players, the competitive landscape of the microbiome diagnostic market to analyze market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation were used.
The four steps involved in estimating the market size are
Collecting Secondary Data
The secondary research data collection process involves the usage of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), annual reports, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the microbiome-based diagnostics market. A database of the key industry leaders was also prepared using secondary research.
Collecting Primary Data
The primary research data was collected after acquiring knowledge about the microbiome diagnostics market scenario through secondary research. A significant number of primary interviews were conducted with stakeholders from both the demand side (such as doctors, nurses, and hospital purchase managers) and supply side (such as included various industry experts, such as Directors, Chief X Officers (CXOs), Vice Presidents (VPs) from business development, marketing and product development teams, product manufacturers, wholesalers, channel partners, and distributors) across major countries of North America, Europe, Asia Pacific, Rest of the World. Approximately 40% of the primary interviews were conducted with stakeholders from the demand side while those from the supply side accounted for the remaining 60%. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.
A breakdown of the primary respondents is provided below:
Breakdown of Primary Participants:
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Tiers are defined based on a company’s total revenue. As of 2022: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
COMPANY NAME |
DESIGNATION |
DNA Genotek (US) |
Manager |
Viome Life Sciences (US) |
VP Sales |
Genetic Analysis AS (Norway) |
Regional Sales Head |
Becton, Dickinson and Company (US) |
Sales Director |
Market Size Estimation
All major product manufacturers offering various microbiome diagnostics were identified at the global/regional level. Revenue mapping was done for the major players and was extrapolated to arrive at the global market value of each type of segment. The market value microbiome-based diagnostics market was also split into various segments and subsegments at the region and country level based on:
- Product mapping of various manufacturers for each type of microbiome diagnostics products at the regional and country level
- Relative adoption pattern of each product type among key application segments at the regional and/or country-level
- Detailed primary research to gather qualitative and quantitative information related to segments and subsegments at the regional and/or country level.
- Detailed secondary research to gauge the prevailing market trends at the regional and/or country-level
Global Microbiome Diagnostics Market Size: Bottom Up Approach
To know about the assumptions considered for the study, Request for Free Sample Report
Global Microbiome Diagnostics Market Size: Top-Down Approach
Data Triangulation
After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the microbiome-based diagnostics industry.
Market Definition
Microbiom diagnostic products are used to investigate and understand the complex communities of microorganisms living in and on the human body. Microbiome diagnostics involves collecting samples from various body sites, such as the skin, gut, mouth, and other mucosal surfaces, and analyzing the genetic material such as DNA, RNA of the microorganisms within these samples.
Key Stakeholders
- Manufacturers and distributors of microbiome-based diagnostics products
- Pharmaceutical and Biotechnology Companies
- R & D centers
- Diagnostic laboratories
- Hospitals and clinics
- Academic institutes
- Research institutes
- Market research and consulting firms
Report Objectives
- To define, describe, segment, and forecast the global microbiome diagnostics market by product, sample, application, end user and region.
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, challenges, and trends)
- To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall microbiome diagnostics market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to four regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
- To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Geographic Analysis
- Further breakdown of the microbiome-based diagnostics market into specific countries/regions in the Rest of Europe, Rest of Asia Pacific, and Rest of the World.
Company Information
- Detailed analysis and profiling of additional market players (up to 3)
Growth opportunities and latent adjacency in Microbiome Diagnostics Market